Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 300.0% in April

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 12,000 shares, an increase of 300.0% from the March 31st total of 3,000 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 73,000 shares, the short-interest ratio is presently 0.2 days.

Virax Biolabs Group Stock Down 1.4 %

Shares of NASDAQ VRAX opened at $0.69 on Friday. Virax Biolabs Group has a 1-year low of $0.61 and a 1-year high of $5.45. The company has a fifty day moving average price of $0.81 and a 200 day moving average price of $1.45.

Hedge Funds Weigh In On Virax Biolabs Group

A hedge fund recently bought a new stake in Virax Biolabs Group stock. Armistice Capital LLC purchased a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 121,999 shares of the company’s stock, valued at approximately $178,000. Armistice Capital LLC owned approximately 7.87% of Virax Biolabs Group at the end of the most recent reporting period. 8.61% of the stock is owned by institutional investors.

About Virax Biolabs Group

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.